Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models

Jun Yan Liu, Yan Ping Lin, Hong Qiu, Christophe Morisseau, Tristan E. Rose, Sung Hee Hwang, Nipavan Chiamvimonvat, Bruce D. Hammock

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Soluble epoxide hydrolase inhibitors (sEHIs) are anti-inflammatory, analgesic, anti-hypertensive, cardio- and renal-protective in multiple animal models. However, the earlier adamantyl-containing urea-based inhibitors are rapidly metabolized. Therefore, new potent inhibitors with the adamantyl group replaced by a substituted phenyl group were synthesized to presumptively offer better pharmacokinetic (PK) properties. Here we describe the improved PK profile of these inhibitors and the anti-inflammatory effect of the most promising one in a murine model. The PK profiles of inhibitors were determined following p.o. administration and serial bleeding in mice. The anti-inflammatory effect of 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), the most promising inhibitor among the five sEHIs tested, was investigated in a lipopolysaccharide (LPS)-challenged murine model. The earlier broadly-used adamantyl-containing sEHI, trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid (t-AUCB), was used for comparison. Compared with the earlier adamantyl-containing urea-based inhibitors, substituted phenyl-containing urea-based inhibitors afford more favorable PK properties, such as higher C maxs, larger AUCs and longer t1/2s, which, as expected, show more stable metabolic stability. Moreover, oral administration of TPPU dramatically reversed the shifts caused by LPS-challenge in plasma levels of inflammatory cytokines, epoxides and corresponding diols, which is more potent than t-AUCB. The substituted phenyl-containing sEHIs are more metabolically stable than those with adamantyl group, resulting in more potent efficacy in vivo. This indicates a new strategy for development of sEHIs for further study toward clinical trials.

Original languageEnglish (US)
Pages (from-to)619-627
Number of pages9
JournalEuropean Journal of Pharmaceutical Sciences
Volume48
Issue number4-5
DOIs
StatePublished - Mar 12 2013

Fingerprint

Epoxide Hydrolases
Urea
Anti-Inflammatory Agents
Pharmacokinetics
Lipopolysaccharides
Benzoic Acid
Epoxy Compounds
Non-Steroidal Anti-Inflammatory Agents
Antihypertensive Agents
Area Under Curve
Oral Administration
Animal Models
Clinical Trials
Hemorrhage
Cytokines
Kidney

Keywords

  • Anti-inflammation
  • Bioavailability
  • Eicosanoids
  • Metabolic profiling
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. / Liu, Jun Yan; Lin, Yan Ping; Qiu, Hong; Morisseau, Christophe; Rose, Tristan E.; Hwang, Sung Hee; Chiamvimonvat, Nipavan; Hammock, Bruce D.

In: European Journal of Pharmaceutical Sciences, Vol. 48, No. 4-5, 12.03.2013, p. 619-627.

Research output: Contribution to journalArticle

Liu, Jun Yan ; Lin, Yan Ping ; Qiu, Hong ; Morisseau, Christophe ; Rose, Tristan E. ; Hwang, Sung Hee ; Chiamvimonvat, Nipavan ; Hammock, Bruce D. / Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. In: European Journal of Pharmaceutical Sciences. 2013 ; Vol. 48, No. 4-5. pp. 619-627.
@article{6eddcbfd330a46d18b1a12ac93e33276,
title = "Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models",
abstract = "Soluble epoxide hydrolase inhibitors (sEHIs) are anti-inflammatory, analgesic, anti-hypertensive, cardio- and renal-protective in multiple animal models. However, the earlier adamantyl-containing urea-based inhibitors are rapidly metabolized. Therefore, new potent inhibitors with the adamantyl group replaced by a substituted phenyl group were synthesized to presumptively offer better pharmacokinetic (PK) properties. Here we describe the improved PK profile of these inhibitors and the anti-inflammatory effect of the most promising one in a murine model. The PK profiles of inhibitors were determined following p.o. administration and serial bleeding in mice. The anti-inflammatory effect of 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), the most promising inhibitor among the five sEHIs tested, was investigated in a lipopolysaccharide (LPS)-challenged murine model. The earlier broadly-used adamantyl-containing sEHI, trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid (t-AUCB), was used for comparison. Compared with the earlier adamantyl-containing urea-based inhibitors, substituted phenyl-containing urea-based inhibitors afford more favorable PK properties, such as higher C maxs, larger AUCs and longer t1/2s, which, as expected, show more stable metabolic stability. Moreover, oral administration of TPPU dramatically reversed the shifts caused by LPS-challenge in plasma levels of inflammatory cytokines, epoxides and corresponding diols, which is more potent than t-AUCB. The substituted phenyl-containing sEHIs are more metabolically stable than those with adamantyl group, resulting in more potent efficacy in vivo. This indicates a new strategy for development of sEHIs for further study toward clinical trials.",
keywords = "Anti-inflammation, Bioavailability, Eicosanoids, Metabolic profiling, Pharmacokinetics",
author = "Liu, {Jun Yan} and Lin, {Yan Ping} and Hong Qiu and Christophe Morisseau and Rose, {Tristan E.} and Hwang, {Sung Hee} and Nipavan Chiamvimonvat and Hammock, {Bruce D.}",
year = "2013",
month = "3",
day = "12",
doi = "10.1016/j.ejps.2012.12.013",
language = "English (US)",
volume = "48",
pages = "619--627",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",
number = "4-5",

}

TY - JOUR

T1 - Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models

AU - Liu, Jun Yan

AU - Lin, Yan Ping

AU - Qiu, Hong

AU - Morisseau, Christophe

AU - Rose, Tristan E.

AU - Hwang, Sung Hee

AU - Chiamvimonvat, Nipavan

AU - Hammock, Bruce D.

PY - 2013/3/12

Y1 - 2013/3/12

N2 - Soluble epoxide hydrolase inhibitors (sEHIs) are anti-inflammatory, analgesic, anti-hypertensive, cardio- and renal-protective in multiple animal models. However, the earlier adamantyl-containing urea-based inhibitors are rapidly metabolized. Therefore, new potent inhibitors with the adamantyl group replaced by a substituted phenyl group were synthesized to presumptively offer better pharmacokinetic (PK) properties. Here we describe the improved PK profile of these inhibitors and the anti-inflammatory effect of the most promising one in a murine model. The PK profiles of inhibitors were determined following p.o. administration and serial bleeding in mice. The anti-inflammatory effect of 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), the most promising inhibitor among the five sEHIs tested, was investigated in a lipopolysaccharide (LPS)-challenged murine model. The earlier broadly-used adamantyl-containing sEHI, trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid (t-AUCB), was used for comparison. Compared with the earlier adamantyl-containing urea-based inhibitors, substituted phenyl-containing urea-based inhibitors afford more favorable PK properties, such as higher C maxs, larger AUCs and longer t1/2s, which, as expected, show more stable metabolic stability. Moreover, oral administration of TPPU dramatically reversed the shifts caused by LPS-challenge in plasma levels of inflammatory cytokines, epoxides and corresponding diols, which is more potent than t-AUCB. The substituted phenyl-containing sEHIs are more metabolically stable than those with adamantyl group, resulting in more potent efficacy in vivo. This indicates a new strategy for development of sEHIs for further study toward clinical trials.

AB - Soluble epoxide hydrolase inhibitors (sEHIs) are anti-inflammatory, analgesic, anti-hypertensive, cardio- and renal-protective in multiple animal models. However, the earlier adamantyl-containing urea-based inhibitors are rapidly metabolized. Therefore, new potent inhibitors with the adamantyl group replaced by a substituted phenyl group were synthesized to presumptively offer better pharmacokinetic (PK) properties. Here we describe the improved PK profile of these inhibitors and the anti-inflammatory effect of the most promising one in a murine model. The PK profiles of inhibitors were determined following p.o. administration and serial bleeding in mice. The anti-inflammatory effect of 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), the most promising inhibitor among the five sEHIs tested, was investigated in a lipopolysaccharide (LPS)-challenged murine model. The earlier broadly-used adamantyl-containing sEHI, trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid (t-AUCB), was used for comparison. Compared with the earlier adamantyl-containing urea-based inhibitors, substituted phenyl-containing urea-based inhibitors afford more favorable PK properties, such as higher C maxs, larger AUCs and longer t1/2s, which, as expected, show more stable metabolic stability. Moreover, oral administration of TPPU dramatically reversed the shifts caused by LPS-challenge in plasma levels of inflammatory cytokines, epoxides and corresponding diols, which is more potent than t-AUCB. The substituted phenyl-containing sEHIs are more metabolically stable than those with adamantyl group, resulting in more potent efficacy in vivo. This indicates a new strategy for development of sEHIs for further study toward clinical trials.

KW - Anti-inflammation

KW - Bioavailability

KW - Eicosanoids

KW - Metabolic profiling

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84873462464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873462464&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2012.12.013

DO - 10.1016/j.ejps.2012.12.013

M3 - Article

C2 - 23291046

AN - SCOPUS:84873462464

VL - 48

SP - 619

EP - 627

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

IS - 4-5

ER -